Imexpharm

Imexpharm EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Imexpharm (IMP.VN) as of Oct 26, 2026 is 309.13. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was 69.54 — a change of 344.51% (higher).

EV/FCF

309.13

YoY

344.51%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Imexpharm is 2025 309.13 . EV/FCF (Enterprise Value to Free Cash Flow) of Imexpharm was 2024 69.54 . It decreases by 344.51% higher compared to the previous year.

The Imexpharm EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2018
-57.21 VND
Jan 1, 2019
-128.02 VND
Jan 1, 2020
-505.41 VND
Jan 1, 2021
46.63 VND
Jan 1, 2022
29.79 VND
Jan 1, 2023
-79.89 VND
Jan 1, 2024
69.54 VND
Jan 1, 2025
309.13 VND
The Imexpharm EV/FCF history
YEAREV/FCFYoY
309.13+344.51%
69.54-187.05%
-79.89-368.16%
29.79-36.11%
46.63-109.23%
-505.41+294.79%
-128.02+123.77%
-57.21+27.80%
-44.77-89.37%
-421.15+60.38%
-262.59-48.27%
-507.67—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Imexpharm Stock analysis

What does Imexpharm do? Imexpharm Corp manufactures and trades pharmaceuticals, medicinal chemicals, and botanical products, including antiseptics, traditional medicine, medical equipment, cosmetics, and supplemental food and drinks. The company provides packaging and warehousing services specifically for pharmaceutical storage. It also cultivates medicinal herbs. Imexpharm Corp serves the pharmaceutical industry and healthcare sector through its manufacturing, import, export, and trade operations, targeting businesses requiring medicinal products and services. The company's revenue streams include the sale of manufactured pharmaceuticals, imported and exported goods, and services such as packaging and warehousing. Its customers are businesses in the healthcare sector, including distributors and retailers of pharmaceuticals, medical equipment, and related products. The firm's operations span manufacturing, import, export, and trade, with additional services supporting the pharmaceutical supply chain. Imexpharm Corp's product portfolio covers a wide range of medicinal and health-related items, from antiseptics to supplemental food and drinks. The company's involvement in medicinal herb cultivation supports its production of traditional medicine and herbal-based products. This vertical integration enhances its ability to supply comprehensive solutions to healthcare businesses. Imexpharm is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Imexpharm stock

EV/FCF (Enterprise Value to Free Cash Flow) of Imexpharm is 309.13 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of Imexpharm changed from 69.54 to 309.13, representing a 344.51% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Imexpharm since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Imexpharm with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Imexpharm

All Key Metrics — Imexpharm